Short-term hemodynamic effects of hydralazine in infants with complete atrioventricular canal defects

Circulation. 1984 May;69(5):949-54. doi: 10.1161/01.cir.69.5.949.

Abstract

We evaluated the acute hemodynamic responses to hydralazine during cardiac catheterization in eight infants (ages 1.0 to 5.5 months) with congestive heart failure due to complete atrioventricular canal defect. Hydralazine administered intravenously (0.5 to 1.0 mg/kg body weight) increased heart rate and systemic blood flow and decreased mean right atrial pressure, systemic and pulmonic arterial pressures, systemic arteriolar resistance, and the ratio of pulmonary to systemic blood flow (p less than .05). The percentage of pulmonary flow contributed by shunted blood (percent left-to-right shunt; measured by indicator dilution) was decreased by hydralazine in six (mean = 85% before to 64% after hydralazine; p less than .01), but remained unchanged (79%) in two infants. The two infants with no change in percent left-to-right shunt had higher pulmonary arteriolar resistances (Rp) before hydralazine (mean = 12.8 vs 3.2 U/m2) and had greater declines in Rp (mean change = -5.1 vs + 0.3 U/m2) in response to hydralazine. Thus, if Rp does not fall, hydralazine reduces the percentage of left-to-right shunt over the short term and therefore might be useful for managing congestive heart failure in these infants. However, because the response varies, an evaluation of the short-term hemodynamic effects of hydralazine may be warranted in an attempt to select those infants who might respond favorably to long-term hydralazine therapy.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blood Circulation / drug effects
  • Blood Pressure / drug effects
  • Endocardial Cushion Defects / drug therapy*
  • Female
  • Heart Failure / drug therapy
  • Heart Rate / drug effects
  • Heart Septal Defects / drug therapy*
  • Hemodynamics / drug effects*
  • Humans
  • Hydralazine / administration & dosage*
  • Infant
  • Male
  • Pulmonary Circulation / drug effects

Substances

  • Hydralazine